Clinical evaluation of the NBD-PC fluorescence polarization assay for prediction of fetal lung maturity.
OBJECTIVE
1) To examine a fluorescence polarization (FP) assay with an independent set of data that contained more cases of respiratory distress syndrome (RDS) than a previous study, 2) to determine whether the same reference ranges are applicable to infants born to diabetic women, and 3) to evaluate whether adding the lecithin-sphingomyelin ratio (L/S) would substantially improve the prediction of RDS among women with an intermediate FP value (between 0.26-0.289).


METHODS
We identified 389 women who had FP analysis performed at the University of Washington Medical Center from February 1986 to October 1988 and who delivered within 3 days of amniocentesis. We reviewed the medical records of these women and their infants to extract information for our study.


RESULTS
For FP values of 0.26 or greater, the sensitivity and specificity for prediction of RDS were 90.2 and 84.6%, respectively, compared with 100 and 82.0% in the previous study. For FP values of 0.29 or greater, the sensitivity and specificity were 62.8 and 94.2%, respectively (80.8 and 96.2% in the previous study). Among diabetics, an FP result below 0.26 was associated with the same low risk of RDS as among non-diabetics. Among the patients with FP between 0.26-0.289, the addition of L/S did not provide a clinically useful improvement in the prediction of fetal lung maturity.


CONCLUSIONS
The NBD-PC FP assay can be used as the sole test of fetal lung maturity in most clinical circumstances.
Chen
C
C
Department of Laboratory Medicine, University of Washington, Seattle.
Roby
P V
PV
Weiss
N S
NS
Wilson
J A
JA
Benedetti
T J
TJ
Tait
J F
JF
D000653:Amniotic Fluid / Q000737:chemistry*; D005069:Evaluation Studies as Topic; D005260:Female; D005325:Fetal Organ Maturity; D005454:Fluorescence Polarization / Q000379:methods; D005865:Gestational Age; D006801:Humans; D007231:Infant, Newborn; D008168:Lung / Q000196:embryology*; D010713:Phosphatidylcholines / Q000032:analysis; D010743:Phospholipids / Q000032:analysis; D011237:Predictive Value of Tests; D011247:Pregnancy; D011254:Pregnancy in Diabetics; D011663:Pulmonary Surfactants / Q000032:analysis*; D012016:Reference Values; D012127:Respiratory Distress Syndrome, Newborn / Q000453:epidemiology; D012680:Sensitivity and Specificity; D013109:Sphingomyelins / Q000032:analysis
D010713:Phosphatidylcholines; D010743:Phospholipids; D011663:Pulmonary Surfactants; D013109:Sphingomyelins; C044745:1-palmitoyl-2-(6-(N-(7-nitrobenz)-2-oxa-1,3-diazol-4-yl)aminocaproyl)phosphatidylcholine